LNTH INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Core Viewpoint - The Lantheus Holdings, Inc. class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly concerning its key product, Pylarify, which is used in prostate cancer diagnosis and treatment [4][5][6]. Group 1: Class Action Details - The class action lawsuit is titled Margolis v. Lantheus Holdings, Inc., and covers purchasers of Lantheus securities from February 26, 2025, to August 5, 2025 [1]. - Investors have until November 10, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Lantheus's executives created a false impression of the company's financial health and growth prospects [4]. Group 2: Allegations and Financial Impact - The lawsuit alleges that Lantheus reported a year-over-year decrease in Pylarify sales due to a "temporal competitive disruption," leading to a significant reduction in growth projections [5]. - Following the disappointing first quarter results announced on May 7, 2025, Lantheus's stock price fell over 23% [5]. - On August 6, 2025, Lantheus announced further disappointing results, with Pylarify sales down 8.3% year-over-year, causing the stock price to drop nearly 29% [6]. Group 3: Company Overview - Lantheus develops and commercializes diagnostic and therapeutic products for heart disease, cancer, and other conditions, with Pylarify being a key product in its portfolio [3].